Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Soliqua

- PMLiVE

EMA begins rolling review of Sanofi, GSK’s COVID-19 vaccine

Rolling review launched based on preliminary results from lab studies and early clinical studies

- PMLiVE

Sanofi signs $1bn licence agreement for Eureka’s novel multiple myeloma drug

Multiple myeloma is the second most common blood cancer

- PMLiVE

AstraZeneca clears latest hurdle for Alexion acquisition after EU clearance

AZ first announced the proposed acquisition of Alexion in December 2020

- PMLiVE

EU identifies first five ‘promising’ COVID-19 drugs as part of therapeutics strategy

The five therapeutic candidates include a repurposed arthritis med and monoclonal antibodies

Sanofi reception

Sanofi to invest €400m annually in mRNA vaccines facility

French pharma company will build end-to-end R&D of ‘next-generation’ mRNA vaccines

- PMLiVE

Lilly showcases tirzepatide type 2 diabetes data at ADA 2021

Company is planning to submit the full data package for tirzepatide to regulatory authorities by the end of 2021

- PMLiVE

Novo Nordisk reveals positive results at ADA 2021 for higher-dose Ozempic in type 2 diabetes

Ozempic 2 mg demonstrated a 2.2% reduction in blood sugar compared with a 1.9% reduction for those receiving Ozempic 1 mg

- PMLiVE

BMS’s oral AML therapy Onureg receives EU approval

Onureg is the oral version of Vidaza, two of the drugs BMS gained as part of its acquisition of Celgene in 2019

Sanofi reception

Sanofi’s oral therapy Aubagio approved in the EU for paediatric MS patients

EC approval comes a few weeks after the FDA rejected Aubagio in the same patient population

- PMLiVE

Court rules on AZ and EU’s COVID-19 vaccine dispute

The Court in Brussels has ordered AZ to deliver a total of 80.2 million doses to the EU by 27 September 2021

Article:

The disparity of patient experiences with Crohn’s Disease in Europe and Japan

Research Partnership

- PMLiVE

AZ’s Tagrisso approved for EGFR-positive NSCLC in the EU

European Commission approved Tagrisso in this setting based on positive results from the ADAURA phase 3 study

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links